Back to top

Analyst Blog

Zacks Equity Research

Becton, Dickinson (BDX) Launch Wireless Diagnostic Device

BAX NUVA BDX GWPH

Trades from $3

Leading global medical technology company Becton, Dickinson and Company (BDX - Free Report) announced the launch of BD Veritor Plus System. It is a wireless rapid diagnostic system for the detection of influenza A and B, respiratory syncytial virus (RSV), and group A strep.

The product is targeted toward health care providers, and laboratorians in physician offices, clinics, hospitals and integrated delivery networks. The BD Veritor Plus System offers new functionalities like user ID, specimen ID and test kit lot. These features would help lower manual documentation and save time.

The BD Veritor Plus System also offers BD Cloud Connectivity Solution. BD Cloud Connectivity Solution is a proprietary technology of the company that allows users to wirelessly transfer test data securely to an electronic medical record (EMR) or a laboratory information system (LIS) to enable data access from anywhere.

Based in Franklin Lakes, NJ, Becton, Dickinson, commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents.

An innovative product pipeline is the key growth driver at BD. A huge number of regulatory approvals both in the U.S. and international markets are facilitating rapid expansion of the company’s product portfolio. BD also has a partnership with Central Admixture Pharmacy Services (CAPS), under which BD Intelliport Medication Management System customers will be allowed to buy a portfolio of frequently used CAPS pre-filled anesthesia syringes.

We believe that such partnerships and collaborations will lend BD a competitive edge and eventually boost its overall results. Although the Zacks Consensus Estimate for the full year has remained unchanged at $8.56 over the last seven days, it reflects year-over-year growth of almost 19.6%.

Zacks Rank & Key Picks

Currently, BD carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical sector include GW Pharmaceuticals plc (GWPH - Free Report) , NuVasive, Inc. (NUVA - Free Report) and Baxter International Inc. (BAX - Free Report) . Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>